Advertisement
Australia markets close in 4 hours 23 minutes
  • ALL ORDS

    7,894.30
    +33.30 (+0.42%)
     
  • ASX 200

    7,638.40
    +32.80 (+0.43%)
     
  • AUD/USD

    0.6439
    +0.0002 (+0.03%)
     
  • OIL

    82.66
    -0.03 (-0.04%)
     
  • GOLD

    2,380.80
    -7.60 (-0.32%)
     
  • Bitcoin AUD

    95,601.79
    -3,553.62 (-3.58%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6033
    +0.0007 (+0.12%)
     
  • AUD/NZD

    1.0880
    +0.0007 (+0.07%)
     
  • NZX 50

    11,814.98
    -60.37 (-0.51%)
     
  • NASDAQ

    17,493.62
    -220.04 (-1.24%)
     
  • FTSE

    7,847.99
    +27.63 (+0.35%)
     
  • Dow Jones

    37,753.31
    -45.66 (-0.12%)
     
  • DAX

    17,770.02
    +3.79 (+0.02%)
     
  • Hang Seng

    16,247.60
    -4.24 (-0.03%)
     
  • NIKKEI 225

    37,856.92
    -104.88 (-0.28%)
     

Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

Phathom Pharmaceuticals
Phathom Pharmaceuticals

FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:30 p.m. ET.

Company management will also participate in one-on-one meetings during the conference which runs from June 8-10, 2022.

To access the live webcast and archived recording of the fireside chat, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recording will be available for 90 days following the event.

ADVERTISEMENT

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). Vonoprazan-based regimens are approved in the U.S. as part of a co-packaged product in combination with antibiotics for the treatment of H. pylori infection in adults, marketed as VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin). Phathom has a New Drug Application under review by the FDA for vonoprazan in erosive esophagitis (EE) and is studying the use of vonoprazan for the treatment of non-erosive reflux disease (NERD). For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.

INVESTOR & MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
ir@phathompharma.com

© 2022 Phathom Pharmaceuticals. All rights reserved.

VOQUEZNA, VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks or trademarks of Phathom Pharmaceuticals, Inc.